Andarine
Andarine
CAS:
Molecular Formula: C19H18F3N3O6
Andarine - Names and Identifiers
Andarine - Physico-chemical Properties
| Molecular Formula | C19H18F3N3O6 |
| Molar Mass | 441.36 |
| Density | 1.47 |
| Melting Point | 70-74℃ |
| Boling Point | 698.7±55.0 °C(Predicted) |
| Water Solubility | 1.2 mg/mL in water |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | neat |
| Color | Light Yellow |
| BRN | 9666695 |
| pKa | 12.13±0.29(Predicted) |
| Storage Condition | Refrigerator |
| In vitro study | In Vitro, Andarine binds with high affinity to the androgen receptor with a K I of 4 nM. Moreover, 10 nM Andarine stimulated androgen receptor-regulated transcription by 93%. |
| In vivo study | In Vivo, Andarine has potent anabolic activity and stimulates the growth of prostate, seminal vesicle, and levator ani muscle with ED50 of 0.43 mg/day and 0.55 mg/day, respectively, and 0.14 mg/day, the effect was dose-dependent. In addition, Andarine acted on FSH, did not affect some physiological changes caused by castration, and treated with 0.5 mg or more per day, partially inhibited LH production. Intravenous administration of 0.1, 1, 3, and 10 mg/kg Andarine to dogs, total body clearance (CL) from 7.4 mL/min/kg to 3.1 mL/min/kg, the steady state volume of distribution (Vss) is 1.39 L/kg, and the Half-Life is 229 minutes. In addition, the oral bioavailability of Andarine at doses of 10 mg/kg, 1 mg/kg, and 0.1 mg/kg was 38%, 62%, and 91%, respectively. Andarine has tissue-selective pharmacological activity and treatment of intact rats at a concentration of 0.5 mg/day significantly reduced prostate weight to 79.4%. |
Andarine - Risk and Safety
| Hazard Symbols | Xi - Irritant |
| Risk Codes | 36 - Irritating to the eyes |
| Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| WGK Germany | 3 |
Andarine - Reference Information
| biological activity | Andarine is a selective non-steroidal androgen receptor (AR)(androgen receptor) agonist with Ki of 4 nM and tissue selectivity for anabolic organs. Phase 3. Andarine (GTx-007, S-4) is a selective non-steroidal androgen receptor (AR)(androgen receptor) agonist with Ki of 4 nM and tissue selectivity for anabolic organs. Phase 3. |
| features | Andarine are non-steroid androgen receptor (AR) selective stimulants. |
| Target | Value |
| Androgen Receptor | 4 nM(Ki) |
Last Update：2024-04-09 19:05:07
